Literature DB >> 30036866

Eribulin in "Field Practice": More from the Italian Experience.

Giulia Valeria Bianchi.   

Abstract

Mesh：

Substances：

Year:  2018        PMID： 30036866      PMCID： PMC6193750          DOI： 10.1159/000489060

Source DB:  PubMed          Journal:  Oncology        ISSN： 0030-2414            Impact factor:   2.935


× No keyword cloud information.
  6 in total

1.  Eribulin induces irreversible mitotic blockade: implications of cell-based pharmacodynamics for in vivo efficacy under intermittent dosing conditions.

Authors:  Murray J Towle; Kathleen A Salvato; Bruce F Wels; Kimberley K Aalfs; Wanjun Zheng; Boris M Seletsky; Xiaojie Zhu; Bryan M Lewis; Yoshito Kishi; Melvin J Yu; Bruce A Littlefield
Journal:  Cancer Res       Date:  2010-12-02       Impact factor: 12.701

2.  We need both randomized trials and real-world data: the example of everolimus as second-line therapy for mRCC.

Authors:  Mimma Rizzo; Giacomo Cartenì; Giovanni Pappagallo
Journal:  Future Oncol       Date:  2014-08-21       Impact factor: 3.404

3.  Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study.

Authors:  Javier Cortes; Joyce O'Shaughnessy; David Loesch; Joanne L Blum; Linda T Vahdat; Katarina Petrakova; Philippe Chollet; Alexey Manikas; Veronique Diéras; Thierry Delozier; Vladimir Vladimirov; Fatima Cardoso; Han Koh; Philippe Bougnoux; Corina E Dutcus; Seth Seegobin; Denis Mir; Nicole Meneses; Jantien Wanders; Chris Twelves
Journal:  Lancet       Date:  2011-03-02       Impact factor: 79.321

Review 4.  Review on the clinical use of eribulin mesylate for the treatment of breast cancer.

Authors:  Olexiy Aseyev; Joana M Ribeiro; Fatima Cardoso
Journal:  Expert Opin Pharmacother       Date:  2016-02-17       Impact factor: 3.889

5.  Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states.

Authors:  T Yoshida; Y Ozawa; T Kimura; Y Sato; G Kuznetsov; S Xu; M Uesugi; S Agoulnik; N Taylor; Y Funahashi; J Matsui
Journal:  Br J Cancer       Date:  2014-02-25       Impact factor: 7.640

6.  Phase II clinical study of eribulin monotherapy in Japanese patients with metastatic breast cancer who had well-defined taxane resistance.

Authors:  Kenichi Inoue; Tsuyoshi Saito; Katsuhiko Okubo; Kei Kimizuka; Hirofumi Yamada; Takashi Sakurai; Kazuo Ishizuna; Satoshi Hata; Toshihiro Kai; Masafumi Kurosumi
Journal:  Breast Cancer Res Treat       Date:  2016-04-28       Impact factor: 4.872
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.